The efficacy of whole-body FDG-PET or PET/CT for autoimmune pancreatitis and associated extrapancreatic autoimmune lesions.
OBJECTIVE
The aim of this study was to evaluate retrospectively the efficacy of whole-body (18)F-fluorodeoxyglucose positron emission tomography (FDG-PET) for autoimmune pancreatitis (AIP) and associated extrapancreatic autoimmune lesions.


METHODS
Whole-body FDG-PET or PET/computed tomography (CT) findings were reviewed in six patients with AIP. The initial PET scans were performed 1 h and 2 h after FDG injection in all six patients. Follow-up PET scans were performed during or following steroid therapy in five patients and in one patient who did not have steroid therapy.


RESULTS
The initial PET scans revealed intense FDG uptake by AIP in all six patients. The maximum standardized uptake value (SUVmax) increased in four patients and was stable in two patients. The intense uptake in the pancreas disappeared during or following steroid therapy in five patients and in one patient who showed spontaneous remission of AIP. Abnormal FDG uptake by extrapancreatic autoimmune diseases was observed in five of the six patients: sclerosing sialadenitis (n = 5), lymphadenopathy (n = 5), retroperitoneal fibrosis (n = 2), interstitial nephritis (n = 2) and sclerosing cholecystitis (n = 1). Abnormal FDG uptake disappeared in the salivary glands (n = 4), lymph nodes (n = 4), retroperitoneum (n = 2), kidneys (n = 1) and gallbladder (n = 1) during or following steroid therapy and remained in the salivary glands and lymph nodes of a spontaneous remission patient.


CONCLUSIONS
These results suggest that whole-body FDG-PET may be useful for detecting AIP and associated extrapancreatic autoimmune lesions and for monitoring their disease activity but that dual time point imaging may not be useful for differentiating malignancy from AIP.
Nakajo
Masatoyo
M
Department of Radiology, Atsuchi Memorial Clinic PET Center, 12-1 Terukuni, Kagoshima City, Japan. toyo.nakajo@dolphin.ocn.ne.jp
Jinnouchi
Seishi
S
Fukukura
Yoshihiko
Y
Tanabe
Hiroaki
H
Tateno
Rie
R
Nakajo
Masayuki
M
D000368:Aged; D001327:Autoimmune Diseases / Q000175:diagnosis*; D005260:Female; D019788:Fluorodeoxyglucose F18; D006801:Humans; D008297:Male; D008875:Middle Aged; D010195:Pancreatitis / Q000175:diagnosis*; D049268:Positron-Emission Tomography / Q000379:methods*; D019275:Radiopharmaceuticals; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D013382:Subtraction Technique; D014057:Tomography, X-Ray Computed / Q000379:methods*; D051598:Whole Body Imaging / Q000379:methods*
D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18
J Gastroenterol. 2006 Jul;41(7):613-25
16932997
Dig Dis Sci. 1995 Jul;40(7):1561-8
7628283
J Nucl Med. 2002 May;43(5):658-63
11994531
Intern Med. 2006;45(21):1243-7
17139126
Scand J Gastroenterol. 2004 Nov;39(11):1154-8
15545176
J Nucl Med. 2004 Sep;45(9):1519-27
15347719
N Engl J Med. 2001 Mar 8;344(10):732-8
11236777
J Clin Gastroenterol. 2005 Nov-Dec;39(10 ):904-7
16208116
JOP. 2005 Jan 13;6(1 Suppl):89-96
15650291
Gut. 2002 Jul;51(1):1-4
12077078
IEEE Trans Med Imaging. 1997 Apr;16(2):145-58
9101324
Eur J Nucl Med. 1998 Sep;25(9):1238-43
9724371
Eur J Nucl Med. 1996 Dec;23 (12 ):1641-74
8929320
Ann Nucl Med. 2001 Jun;15(3):217-24
11545191
Pancreatology. 2005;5(2-3):300-3
15855829
Nucl Med Biol. 1998 May;25(4):317-22
9639291
Arthritis Rheum. 2005 Apr 15;53(2):298-303
15818649
Eur J Nucl Med Mol Imaging. 2007 Mar;34(3):392-404
17033848
Clin Nucl Med. 2007 Apr;32(4):282-5
17413574
Eur J Nucl Med. 2000 Dec;27(12 ):1835-8
11189947
Arch Pathol Lab Med. 2005 Sep;129(9):1148-54
16119989
J Nucl Med. 2001 Sep;42(9):1412-7
11535734